Consider the position of an independent veterinary imaging equipment vendor. The company sells ultrasound machines, or digital radiography systems, or CT scanners, to veterinary practices. It competes the way the antitrust laws assume companies compete: on the quality of its equipment, on the price it can offer, on the training it provides, on the service contract that stands behind the sale. It employs salespeople who know the practices in their territory, who have spent years building relationships, who understand the clinical needs of a small-animal hospital deciding whether it is ready for in-house CT.

And increasingly, that company loses. Not to a better machine. Not to a lower honest price. It loses because a corporate diagnostic company walked into the same clinic and offered the same category of equipment at no upfront cost at all — bundled into a multi-year laboratory-services contract. The clinic looks at one quote with a real number on it and another arrangement where the number is zero, and the clinic, understandably, takes the zero. The independent vendor did not lose a fair fight. It was never in one.

This article is about that arrangement: the bundling of veterinary laboratory services with imaging equipment, and increasingly with PACS and teleradiology, into a single corporate package that the independent equipment vendor cannot match. It is written deliberately from the equipment vendor’s perspective, because the vendor’s perspective makes the harm visible in a way the clinic’s perspective does not. The clinic sees a good deal. The vendor sees a market closing. And behind the vendor, mostly invisible, stands the pet owner who will ultimately pay for the free CT scanner without ever being told.

The article documents what the bundling model is, why the equipment vendor cannot compete with it, the federal antitrust framework that governs it, how the model forecloses not just equipment but PACS and teleradiology, who operates it, how it can be enforced, and what the penalties are. It treats the bundling as a structure and analyzes that structure against the law. It does not adjudicate any specific company’s specific deal — but it does name the companies whose bundling is well established in the market, and it explains, precisely, why the structure raises a serious antitrust concern.

The Offer the Clinic Receives

The arrangement, in its typical form, is straightforward and attractive. A corporate diagnostic company — a company whose core business is veterinary laboratory services, the bloodwork and pathology and reference-lab diagnostics that every small-animal practice needs — approaches a veterinary clinic. It offers the clinic imaging equipment: an ultrasound machine, a digital radiography system, sometimes a CT scanner, along with the picture archiving and communication system, the PACS, that stores and manages the images. The equipment is offered at no upfront cost, or at a discount steep enough that the difference from free is immaterial to the clinic’s decision.

The condition is a laboratory-services contract. The clinic commits to sending its laboratory diagnostics — its bloodwork, its pathology, its reference-lab testing — to the diagnostic company, for a multi-year term, often with minimum-volume commitments. The clinic signs. It receives equipment it might otherwise have financed over years or done without. From the clinic’s chair, this is a good day: it got the CT scanner it wanted, and it did not have to write a capital check for it.

Why “Free” Is Not Free

The equipment is not free, and understanding precisely why is the foundation of everything that follows. The corporate diagnostic company is not a charity, and it did not forget to charge for a CT scanner. The cost of that equipment — the real cost, the cost the independent vendor would have had to put on a quote — is recovered by the diagnostic company over the life of the laboratory contract. It is embedded in the per-test pricing the clinic agrees to. It is embedded in the minimum-volume commitments. It is amortized across years of laboratory invoices that the clinic will pay without ever seeing a line item that says “CT scanner.”

The clinic has not avoided paying for the equipment. It has financed the equipment — through its laboratory spend, on terms set entirely by the company that controls both the equipment and the lab relationship, and at an effective interest rate the clinic cannot calculate because the cost was never disclosed as a separate number. The clinic traded a visible, comparable, negotiable equipment price for an invisible, non-comparable, locked-in stream of laboratory charges. That is not a discount. It is a refinancing — of a purchase the clinic could have shopped competitively — into an instrument the clinic cannot shop at all.

Two Separate Products, Tied Together

The structural fact that matters legally is this: laboratory services and imaging equipment are two separate products. A veterinary clinic needs laboratory diagnostics. A veterinary clinic separately needs, or wants, imaging equipment. These are distinct markets with distinct competitors — reference laboratories on one side, imaging-equipment manufacturers and vendors on the other. There is no clinical or technical reason the two must be bought together. A clinic could buy its lab services from one company and its ultrasound machine from another, and for a long time that is exactly how the market worked.

The bundle ties them. It conditions the attractive terms on the imaging equipment — the zero upfront cost — on the clinic’s agreement to take laboratory services from the same company. The clinic that wants the equipment deal cannot take it standalone; it must take the lab contract with it. And the economics of the lab contract are shaped, invisibly, by the cost of the equipment being amortized inside it. Two separate products, one of which the company has built its business around, the other of which it is using that business to place into clinics on terms no standalone equipment vendor can match. When a company conditions the sale of one product on the purchase of a separate product, the arrangement has a name in federal antitrust law. It is a tying arrangement. And tying arrangements, under the right conditions, are unlawful.

Tying Is Not Automatically Illegal — and That Precision Matters

It is important to state plainly what the law does not say. Federal antitrust law does not prohibit bundling as such. Companies sell products together all the time, and customers often benefit from genuine bundle discounts. A diagnostic company offering a clinic a package of services is not, by the mere fact of packaging, doing anything unlawful. An article that claimed otherwise would be wrong, and a reader — particularly a regulator or a lawyer — would rightly stop trusting it. So the analysis has to be precise.

A tying arrangement becomes unlawful under Section 1 of the Sherman Act, and is separately reachable under the Clayton Act, when a specific set of conditions is satisfied. There must be two genuinely separate products — the tying product and the tied product. The seller must possess appreciable economic power, meaningful market power, in the tying product market. The arrangement must foreclose or affect a substantial volume of commerce in the tied product market. And the arrangement must operate to coerce buyers — to force purchases in the tied market that the buyers would not otherwise have made on the merits. Where those conditions are met, a tying arrangement can be condemned, in the clearest cases without an extended inquiry into its reasonableness, and in other cases under the rule of reason.

Apply that framework to veterinary diagnostic bundling. The two separate products are plainly present: laboratory services and imaging equipment are distinct markets. The coercion element is visible in the structure: the clinic cannot get the equipment terms without the lab contract. The two questions that determine legal exposure are therefore the market-power question and the foreclosure question — does the diagnostic company hold meaningful market power in veterinary laboratory services, and does its equipment bundling foreclose a substantial volume of the independent imaging-equipment market? Those are fact-specific questions. But they are not difficult questions to take seriously when the veterinary laboratory-services market is dominated by a small number of very large companies, and when independent equipment vendors report losing deal after deal to bundled arrangements they cannot match.

The Kodak Parallel

There is a directly instructive precedent. In Eastman Kodak Co. v. Image Technical Services, the U.S. Supreme Court addressed a tying arrangement in which Kodak used its position to foreclose independent service organizations — independent companies that serviced Kodak equipment — from the market. The independent service organizations were, in the Court’s account, driven out of business by Kodak’s policies. The case is a foundational illustration of the principle that a firm can violate the antitrust laws by using power in one market to foreclose independent competitors in a connected market, even where the firm faces competition in the first market.

The parallel to veterinary equipment bundling is close enough to be uncomfortable. Substitute the independent imaging-equipment vendor for the independent service organization. Substitute the corporate diagnostic company’s laboratory-services position for Kodak’s position. The mechanism is the same: a firm with power in one market structuring arrangements that foreclose independent competitors in a connected market — not by building a better product, not by offering a lower honest price, but by leveraging the first market to capture the second. Kodak stands for the proposition that the antitrust laws see that mechanism and condemn it when the elements are met.

Below-Cost Pricing and Exclusive Dealing

Tying is the primary frame, but it is not the only antitrust concern the bundling model raises. Two others deserve mention because they apply directly to the way the model actually operates.

The first is predatory or below-cost pricing. When a product is offered not merely at a discount but below its real cost — when equipment is given away, or teleradiology reads are tossed into a bundle at a price that cannot cover the cost of board-certified specialist interpretation — the conduct raises the distinct concern of predatory pricing: the use of below-cost pricing to drive competitors out of a market or to make a bundle impossible for independents to match. The second is exclusive dealing. A multi-year laboratory contract with minimum-volume commitments, tied to equipment the clinic would lose if it left, functions as an exclusive-dealing arrangement: it locks the clinic’s diagnostic spend to one company and forecloses competitors from bidding for that clinic’s business for the contract’s duration. Exclusive-dealing arrangements are themselves scrutinized under the antitrust laws when they foreclose a substantial share of a market.

The veterinary diagnostic bundle, in other words, is not a single antitrust question. It is a cluster of them — tying, below-cost foreclosure, and exclusive dealing — operating together, each reinforcing the others, all pointing at the same outcome: the foreclosure of independent competitors in equipment, in PACS, and in teleradiology.

Competing Against a Price That Is Not Real

Return to the independent equipment vendor, because the vendor’s predicament is the heart of this article. The vendor is sometimes told, in effect, to compete harder — to lower its price, to improve its service, to win on the merits. That advice misunderstands the problem. The vendor is not losing on the merits. The vendor is losing because it is being asked to compete against a price that is not real.

The independent vendor’s price is real. It reflects the actual cost of the equipment plus a margin the vendor needs to survive. The vendor can shave that margin, and many have, until there is nothing left to shave. It cannot shave its way to zero, because the equipment genuinely costs money and the vendor has no second revenue stream to hide the cost in. The corporate diagnostic company does have that second stream — the laboratory contract — and so it can present the clinic with a number the independent vendor structurally cannot present: zero. Not a lower number. Zero. The independent vendor cannot beat zero by competing harder, because the gap between its honest price and zero is not inefficiency the vendor can wring out. It is the cost of the equipment, which is real, and which someone always pays.

The Market Closes Quietly

Foreclosure in this form does not happen with a dramatic event. No independent equipment vendor is told it may not sell. It simply loses, deal after deal, to an arrangement it cannot match — and then, eventually, it stops being able to keep its salesforce employed, stops being able to fund the next generation of its product, and exits. Each individual loss looked like an ordinary competitive outcome. The clinic chose the bundle; the bundle was attractive; nothing visibly improper occurred in that single transaction. But the aggregate of those transactions is a market in which the independent equipment vendors are gone, and the only remaining sources of veterinary imaging equipment are the corporate diagnostic companies whose bundles drove the independents out.

That is the foreclosure the antitrust laws are concerned with. Not a single coerced sale, but the cumulative closing of a market to competition on the merits. And once the independent vendors are gone, the discipline they provided is gone with them: the competition on equipment quality, the competition on honest price, the competition on service and training, the innovation that independent vendors drove because they had to differentiate to survive. The clinic that took the bundle has fewer choices the next time. The clinic that would have preferred to buy honestly from an independent finds there is no independent left to buy from.

Teleradiology and PACS — The Bundle Extends

The foreclosure does not stop at equipment. A clinic that has acquired bundled imaging equipment needs the images managed, which means PACS — and the PACS is in the bundle. It needs the images interpreted, which means radiology — and increasingly the teleradiology read is in the bundle too, offered at a deep discount or as a near-free add-on that sweetens the package. This publication has documented the teleradiology dimension directly: the integration of the VitalRads teleradiology service into the Zoetis Virtual Laboratory platform folds specialist radiology interpretation into a major diagnostics portfolio, and this publication’s broader coverage of IDEXX’s radiology vertical integration and the Mars-Antech diagnostic structure documents how laboratory, imaging, and interpretation are assembled under single corporate ownership.

Each market folded into the bundle is another market in which independent competitors are foreclosed by something other than the merits. The independent teleradiology provider that prices its reads to reflect the real cost of board-certified specialist interpretation cannot match a near-free read dropped into a lab-and-equipment bundle — exactly as the independent equipment vendor cannot match free equipment. The fully developed veterinary diagnostic bundle ties together four markets — laboratory services, imaging equipment, PACS, and teleradiology — into one corporate relationship governed by one multi-year contract. Four markets, and in three of them independent competitors are being foreclosed by the leverage of the fourth.

The Companies Operating the Model

The bundling of laboratory services with imaging equipment and related diagnostics is well established among the largest companies in veterinary diagnostics. IDEXX and Antech are the dominant laboratory-services companies in the U.S. veterinary market, and both pair laboratory relationships with imaging hardware and related diagnostic infrastructure. IDEXX operates a diagnostic ecosystem that spans reference-laboratory services, in-clinic analyzers, imaging hardware, and practice-management software; this publication has separately documented the structure of that vertical integration and the terms of IDEXX’s telemedicine and diagnostic contracts. Antech operates within the Mars veterinary diagnostic and clinic structure, which this publication has documented in detail.

The pattern is also extending through new alliances. In August 2025, Zoetis — described as the world’s leading animal health company — announced a partnership integrating the VitalRads teleradiology service into the Zoetis Virtual Laboratory, the company’s diagnostics platform. That integration folds specialist radiology interpretation into a major laboratory-and-diagnostics portfolio, the same structural move that brings teleradiology inside the bundle. This publication has covered the VitalRads dimension in its analysis of VitalRads and its private-equity context.

This article describes the bundling model structurally rather than reciting the specific equipment transactions of any one company, because the antitrust concern attaches to the structure. The legal question for each company is whether its particular arrangements satisfy the elements of an unlawful tie — whether it holds market power in laboratory services, and whether its equipment and teleradiology bundling forecloses a substantial share of those markets. That is a fact-specific question this article frames and does not purport to answer against any named company. What the article does establish is that the structure is real, that the companies named operate within it, and that the structure raises a serious and legitimate antitrust concern that the foreclosed competitors, the agencies, and the courts are entitled to examine.

The Pet Owner Pays for the Free Machine

The harm of equipment bundling is often framed as a harm to equipment vendors, and it is — but the equipment vendor is not the only one paying, and is not even the one paying most. The pet owner pays.

Trace the money. The corporate diagnostic company recovers the cost of the free equipment through the laboratory contract. The clinic, locked into that contract, pays laboratory pricing that was never disciplined by open competition — the clinic cannot shop its bloodwork to a lower-priced or higher-quality laboratory, because it is contractually bound and because leaving would forfeit the equipment arrangement. Laboratory pricing set inside a bundle is insulated pricing, and insulated pricing runs higher than competitively bid pricing. The clinic absorbs that elevated cost and, as every business must, passes it through to its customers. The customer is the pet owner.

So the pet owner funds the free CT scanner — not as a line item, not as a disclosed charge, but as a diffuse markup spread invisibly across years of laboratory invoices, on diagnostics for their own animal, to pay for a machine they will never see in a clinic they may never visit. The bundle did not conjure a free machine out of nothing. It moved the cost of that machine from a visible, comparable, negotiable equipment price into an invisible, non-comparable stream of laboratory charges paid by people who were never told. The pet owner is the ultimate funder of the entire arrangement, and the pet owner is the one party to the whole structure who never had a seat at the table.

How It Can Be Enforced — and the Remedy the Vendor Holds Itself

Unlawful tying, below-cost foreclosure, and exclusive dealing can be addressed through several channels. The federal antitrust agencies — the Department of Justice Antitrust Division and the Federal Trade Commission — have authority to investigate and challenge these practices under the Sherman Act, the Clayton Act, and the Federal Trade Commission Act. State attorneys general have parallel enforcement authority under federal antitrust law and under state antitrust and unfair-competition statutes.

But the most important enforcement pathway, for the audience this article is written for, is the one the foreclosed competitor holds in its own hands. Federal antitrust law provides a private right of action. A business injured by an unlawful tying arrangement — an equipment vendor foreclosed from sales it would have made but for a competitor’s unlawful bundle — can bring its own antitrust suit. And the remedy is deliberately powerful: a successful private antitrust plaintiff recovers treble damages, three times the actual damages proven, together with attorney’s fees, and can obtain an injunction against the unlawful practice. The treble-damages structure exists precisely so that injured competitors have both the incentive and the means to enforce the antitrust laws themselves, without waiting for a government agency to assign the matter priority.

For the independent equipment vendor watching deal after deal vanish into bundles it cannot match, that is not an abstract point. It means the vendor is not solely dependent on whether a federal agency takes interest. If the elements of an unlawful tie are present — market power in laboratory services, substantial foreclosure of the equipment market — the foreclosed vendor has standing, a cause of action, and a treble-damages remedy. The conditions that have kept this conduct unchallenged are not legal immunity. They are the absence, so far, of a plaintiff willing to document the foreclosure and bring the case.

What the Penalties Are

The exposure for unlawful tying and related anticompetitive conduct is substantial. Government enforcement can produce injunctive relief restructuring or prohibiting the arrangements, civil penalties, and consent decrees imposing ongoing compliance obligations. Private litigation can produce treble-damages judgments — and in a market where bundling has foreclosed equipment sales across many clinics over many years, the actual damages, before trebling, can be large; trebled, they become a serious financial exposure. Attorney’s-fee shifting means a meritorious private plaintiff is not deterred by litigation cost. And the reputational and business consequences of an adverse antitrust judgment, for a company whose customers are veterinarians increasingly attentive to corporate consolidation in their profession, are not trivial.

The penalties, in short, are real, they are enforceable through multiple channels, and one of those channels belongs to the injured competitor directly. The veterinary equipment bundling model has operated for years without a serious legal challenge. That is a fact about enforcement history. It is not a fact about whether the conduct is lawful.

The Two Fields, Side by Side

Element	Honest Equipment Competition	The Lab-Contract Bundle
Equipment price the clinic sees	A real number reflecting real cost plus margin	Zero, or near zero, upfront
Who pays for the equipment	The clinic, transparently, at a comparable price	The clinic, invisibly, through inflated lab pricing — passed to pet owners
Basis of competition	Equipment quality, price, service, training	Leverage of market power in a separate market
Independent equipment vendor	Can compete and win on the merits	Foreclosed — cannot match a subsidized zero
Clinic’s lab pricing	Disciplined by open competition	Locked in, insulated from competition for the contract term
Clinic’s freedom to switch labs	Free to shop bloodwork competitively	Contractually bound; leaving forfeits the equipment
PACS and teleradiology	Chosen independently on the merits	Folded into the same bundle; independents foreclosed
Antitrust posture	Competition on the merits — what the law protects	Tying, below-cost foreclosure, exclusive dealing — what the law scrutinizes

---

---